Skip to main content
Fig. 5 | Journal of Biomedical Science

Fig. 5

From: Interleukin-20 is involved in dry eye disease and is a potential therapeutic target

Fig. 5

7E treatment improved BAC-induced dry eye symptoms in mice. Mice were topically administered PBS or BAC twice daily for 2 weeks to induce DED. PBS, Xiidra, mIgG, or 7E was administered twice daily beginning on day 8 (n = 5, each group). a Corneal fluorescein staining was performed to analyze the integrity of the corneal epithelium. Representative images were taken with a cobalt blue filter by a Micron IV. b The fluorescein scores were blindly evaluated by four individuals. One-way ANOVA, *p < 0.05, ***p < 0.001, and ****p < 0.0001. Data are shown as the mean ± SEM. Arrow indicates the treatment started on day 8. c Tear production was measured at the same time of day in the standard environment. One-way ANOVA, *p < 0.05, **p < 0.01, and ***p < 0.001. Data are shown as the mean ± SEM. d H&E staining was performed to observe corneal morphology. Original magnification: ×400. e The corneal mRNA transcripts of Il1b, Il6, Icam1, Mcp1, and Il10 were analyzed by real-time PCR with specific primers. Gapdh was used as an internal control. One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Data are shown as the mean ± SEM. The experiments in a–e were repeated three times independently with similar results, and the data of one representative experiment was shown. BAC benzalkonium chloride, DED dry eye disease

Back to article page